Analyst Price Targets — OKUR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 14, 2026 12:09 pm | — | Oppenheimer | $14.00 | $3.92 | TheFly | OnKure Therapeutics price target lowered to $14 from $30 at Oppenheimer |
| October 10, 2024 6:12 am | Matt Biegler | Oppenheimer | $35.00 | $18.50 | TheFly | OnKure Therapeutics initiated with an Outperform at Oppenheimer |
Latest News for OKUR
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026.
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027
OnKure Therapeutics NASDAQ: OKUR used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.
BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences).…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OKUR.
U.S. House Trading
No House trades found for OKUR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.